Loading...
APEN logo

Apollo Endosurgery, Inc.NasdaqGM:APEN 株式レポート

時価総額 US$579.7m
株価
n/a
私の公正価値
n/a
1Y67.8%
7D0.8%
1D
ポートフォリオ価値
​
表示

Apollo Endosurgery, Inc.

NasdaqGM:APEN 株式レポート

時価総額：US$579.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Apollo Endosurgery（APEN）株式概要

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. 詳細

APEN ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長2/6
過去の実績0/6
財務の健全性5/6
配当金0/6

報酬

収益は年間32.05%増加すると予測されています

リスク分析

過去1年間で株主の希薄化が進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない


APEN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Apollo Endosurgery, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Apollo Endosurgery
過去の株価
現在の株価US$10.00
52週高値US$10.30
52週安値US$3.49
ベータ2.32
1ヶ月の変化0.50%
3ヶ月変化1.11%
1年変化67.79%
3年間の変化360.83%
5年間の変化70.94%
IPOからの変化-17.76%

最新ニュース

分析記事 • Apr 03

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 30

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Recent updates

分析記事 • Apr 03

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 30

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Aug 05

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 04

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Apollo Endosurgery came in with another strong quarter of top-line growth whilst growing gross margins on the same. The company saw substantial growth in each of its key segments, coupled with regulatory momentum in its Apollo ESG and REVISE series. Valuations are also supportive and we look to be getting shares on the cheap here at ~4.3x book value, as illustrated. We rate APEN a buy and value its stock at $7.97 per share. Investment Summary We continue our medtech earnings coverage with Apollo Endosurgery, Inc. (APEN), manufacturer of bariatric surgery systems. It was a strong Q2 FY22 for the company with upsides in revenue versus consensus, although it missed estimates below the bottom line. Despite this, fundamental momentum continues brewing for the company, and we note it's caught a bid in H2 FY22 alongside the broad sector. Valuations are supportive and we are paying ~4x book value for a company that grew its top 10 accounts by more than 53% YoY last quarter. With this in mind, we rate APEN buy with price target of $7.97. Exhibit 1. APEN 6-month price target Data: Refinitiv Q2 earnings illustrate current investor challenges Second-quarter earnings were mixed with upsides versus consensus in revenue but a miss in EPS. Worldwide revenue was 16% higher YoY at $19 million with ~310bps of forex tailwinds. Turnover increased due to an 18% increase in US product sales and 15% ex-US, adjusted to 23% on constant currency. The company's top 10 accounts saw a 53% YoY increase. Segmentally, Endoscopic Suturing System ("EES") sales stretched up 23% YoY to $2.4 million backed by demand for OverStitch and X-Tack. Meanwhile, its intragastric balloon ("IGB") segment grew 6% YoY. As seen in Exhibit 2, it was an above-average performance for the company, with its strongest quarterly result in years. Exhibit 2. Quarterly operating performance has been ratcheting up across FY21 to date, with share price and top-line fundamentals starting to converge Data: HB Insights; APEN SEC Filings Gross margin on these revenues lifted ~180ps YoY to 56.8% from higher product sales. As seen above, it continues to curl up alongside top-line performance. This is a bullish factor seeing the company is strengthening margins into a weakening global economic outlook. Moving down the P&L, OPEX increased to $17.6 million as the company increased its salesforce headcount in H2 FY21, plus the marketing spend with this. Operating loss on this was ~$6.5 million. It carried this down to a net loss of $10.4 million for the quarter, versus a net loss of $3 million the quarter prior. The delta was attributed to the forgiveness of the Paycheck Protection Program ("PPP") loan a year beforehand. The company left the quarter well capitalized with $140 million in "committed cash" despite a net loss on CFFO of $14.7 million, worse than the loss of $6.4 million in Q2 FY21. Ex-committed cash, it had ~$75.5 million in cash on the balance sheet. As seen in Exhibit 3, on its net cash spend of $14.7 million and ending balance of $~$75.5 million for the quarter, we estimate the company has ~1.5 years of runway left before having to re-evaluate the situation. Exhibit 3. Data: HB Insights Estimates; APEN SEC Filings With the exit momentum leaving Q2 management reiterated FY22 full-year guidance. This expects to land between $73-75 million with potential 400bps of forex headwinds. Regulatory tailwinds The company also received the nod from the FDA for De Novo marketing authorization for Apollo ESG and Apollo REVISE. Apollo ESG is an interesting segment with favourable economics tied into the mix. It is used in bariatric surgery, or treatment of patients with obesity. Both systems are the first FDA-authorized systems for "endoscopic sleeve gastroplasty". This is a minimally invasive procedure to help obesity patients in reduction of body mass. APEN indicates it for those with BMI range of 30–50kg/m2 who require bariatric surgery. Both systems and the gastroplasty procedure were also featured in the publication of the MERIT study in late July, in the LANCET journal. Per the company's investor presentation yesterday, from the study readouts: The MERIT study proves that ESG is scalable and can be offered in outpatient endoscopy practices by surgeons or gastroenterologists, with an excellent safety profile, without mortality, and with predictable conservatively managed adverse events. Intra-operative hardware used in the Apollo ESG and Apollo REVISE procedures. Image: APEN Valuation Shares are trading at around 4.2x book value and 4x sales, both below the GICS Industry median respectively. The peer group is a strong one and Apollo's lack of profitability makes it difficult to assign a concrete valuation. It printed a quarterly ROA of -8.6% and this is in line with longer term trends. Investors also realize a negative 22% ROE from the most recent quarter's results.
分析記事 • Mar 02

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Aug 04

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Today we will run through one way of estimating the intrinsic value of Apollo Endosurgery, Inc. ( NASDAQ:APEN ) by...
Seeking Alpha • Jun 28

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Apollo Endosurgery is a medical device company developing innovative medical devices to advance gastrointestinal therapeutic endoscopy. The company's share price is +421% over the past 12 months and +130% since the arrival of a new CEO, Charles "Chas" McKhann in February. Although revenues fell ~18% between FY19 and FY20 owing to pandemic pressures, management is guiding for $55-57m of revenues in FY21. The company has 3 exciting growth opportunities - breakthrough device designation for its gastric balloon in NASH, a stand-alone weight loss indication for its OverStitch suturing device, and newly launched X-Tack. As such, shares still look cheap at ~$8.6, and a market cap of $233m undervalues the company and its opportunities, in my view.
分析記事 • May 05

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Mar 24

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Apollo Endosurgery...
分析記事 • Mar 03

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Every investor in Apollo Endosurgery, Inc. ( NASDAQ:APEN ) should be aware of the most powerful shareholder groups...
分析記事 • Feb 10

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Potential Apollo Endosurgery, Inc. ( NASDAQ:APEN ) shareholders may wish to note that insider Neil Gagnon recently...
分析記事 • Jan 31

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
分析記事 • Dec 27

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

It is doubtless a positive to see that the Apollo Endosurgery, Inc. ( NASDAQ:APEN ) share price has gained some 155% in...
分析記事 • Dec 01

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Apollo Endosurgery, Inc. (NASDAQ:APEN), is not the largest company out there, but it led the NASDAQGM gainers with a...

株主還元

APENUS Medical EquipmentUS 市場
7D0.8%4.4%1.0%
1Y67.8%-17.9%28.7%

業界別リターン: APEN過去 1 年間で-17.9 % の収益を上げたUS Medical Equipment業界を上回りました。

リターン対市場: APEN過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。

価格変動

Is APEN's price volatile compared to industry and market?
APEN volatility
APEN Average Weekly Movement0.5%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: APEN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: APENの 週次ボラティリティ は、過去 1 年間で12%から1%に減少しました。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
2005202Chas McKhannwww.apolloendo.com

Apollo Endosurgery, Inc. 基礎のまとめ

Apollo Endosurgery の収益と売上を時価総額と比較するとどうか。
APEN 基礎統計学
時価総額US$579.72m
収益（TTM）-US$39.84m
売上高(TTM)US$76.86m
7.5x
P/Sレシオ
-14.6x
PER（株価収益率

APEN は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
APEN 損益計算書（TTM）
収益US$76.86m
売上原価US$34.43m
売上総利益US$42.43m
その他の費用US$82.27m
収益-US$39.84m

直近の収益報告

Dec 31, 2022

次回決算日

該当なし

一株当たり利益（EPS）-0.69
グロス・マージン55.20%
純利益率-51.84%
有利子負債／自己資本比率164.7%

APEN の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2023/04/06 12:29
終値2023/04/03 00:00
収益2022/12/31
年間収益2022/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Apollo Endosurgery, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8

アナリスト機関
Matthew HewittCraig-Hallum Capital Group LLC
Frank TakkinenLake Street Capital Markets, LLC
Suraj KaliaNorthland Capital Markets